Asciminib improves outcomes in chronic myeloid leukemia
1. In this randomized controlled trial, among adults diagnosed with chronic myeloid leukemia (CML), asciminib demonstrated a significantly higher major ...
Tag: CLL
Venetoclax monotherapy effectively treats relapsed or refractory chronic lymphocytic leukemia
1. VENICE-1 observed high response rates (complete or partial remission) in both BCRi-naïve and BCRi-pretreated patients with refractory or relapsed ...
#VisualAbstract: Chronic Lymphocytic Leukemia (CLL) therapy with Ibrutinib and Venetoclax guided by measurable residual disease improves progression-free survival
Click here to read this study in NEJM. ©2024 2 Minute Medicine, Inc. All rights reserved. No works may be reproduced without ...
#VisualAbstract: Ibrutinib-Venetoclax Improves Progression-Free Survival in Chronic Lymphocytic Leukemia
Click here to read this study in NEJM. ©2023 2 Minute Medicine, Inc. All rights reserved. No works may be reproduced without expressed ...
Venetoclax in addition to ibrutinib effective as a treatment for chronic lymphocytic leukemia
1. High genetic risk participants with chronic lymphocytic leukemia (CLL) taking venetoclax in addition to ibrutinib achieved high rates of ...
#VisualAbstract: Pirtobrutinib is safe and efficacious in the treatment of relapsed or refractory B-cell malignancies (BRUIN Trial)
1. Bruton’s tyrosine kinase inhibitor pirtobrutinib showed efficacy in the treatment of relapsed or refractory B-cell malignancies such as chronic ...
Combined lenalidomide and rituximab dose escalation found to be safe for CLL
Image: PD 1. Most treatment-naïve patients with chronic lymphocytic leukemia (CLL) safely tolerated escalating doses of combined lenalidomide and rituximab. 2. ...
Rituximab linked with reduced chronic immune disease following stem cell transplantation
Image: PD AML 1. Rituximab use is linked with a reduction in chronic graft-vs-host disease following peripheral blood stem cell ...